
Oncology Business Management
Latest News

Advertisement
Latest Videos

Advertisement
More News

As rumors circulate in Washington, DC, ASCO has called for efforts to reach a consensus on drug value to ensure affordability and access for patients and spur manufacturers to work harder on bringing innovative medicines to market.

The FDA’s Oncologic Drugs Advisory Committee voted 16-0 to recommend approval to MYL-1401O, the trastuzumab (Herceptin) biosimilar manufactured by Mylan Pharmaceuticals.











The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.












Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for High-Grade, Papillary-Only BCG-Unresponsive NMIBC
2
SurVaxM Cancer Vaccine Shows Clinically Meaningful OS Signal in Newly Diagnosed Glioblastoma
3
VS-7375 Elicits Responses in KRAS G12D–Mutated Pancreatic Cancer
4
FDA Receives NDA Resubmission for Rivoceranib Plus Camrelizumab in Frontline Unresectable or Metastatic HCC
5










































































